Sign in with your work email to save this update, triage it, and track follow-up.
Sign in to saveThe FDA is introducing draft guidance that outlines new labeling expectations regarding drug interactions and QTc information. These guidelines will result in stricter organizational and content requirements in the labeling sections related to drug interactions and QTc, effective by the completion of the review period for the draft guidance.
This guidance will standardize drug interaction and QTc interval documentation across the pharmaceutical industry, potentially minimizing the risk of adverse interactions and improving patient safety outcomes. Companies will need to align their practices with these updated standards to ensure compliance.
Sign in to unlock the full action card and owner assignment.
Sign in with your work email to read the full operational brief, action card, and evidence ledger.
Sign in with your work email to unlock the full briefing, regulatory action card, evidence ledger, and role-specific next steps.
PV teams should update workflows and SOPs to include the new section 19A approval processes and ensure compliance with the TGA's guidelines for managing medicine shortages.
PV teams should update their workflows regarding inspection readiness, review standard operating procedures (SOPs) to align with the new GCP inspection coordination processes, and ensure that all relevant personnel are trained on the updated guidance.
PV teams should review and update their Standard Operating Procedures (SOPs) related to real-world data collection methodologies and ensure alignment with the new guidance emerging from the workshop. Training may also be required to enhance understanding of RWD's impact on regulatory submissions.
PV teams should update their regulatory intelligence monitoring workflows to include the timelines and requirements established by the EMA for thalassaemia treatments. It's essential to ensure adherence to the new guidelines in clinical trial designs.
